To understand the immune landscape of deficient mismatch repair colorectal cancer (dMMR CRC) tumor microenvironment, gene expression profiling was performed by the nCounter PanCancer Immune Profiling Panel. This study was conducted retrospectively on 89 dMMR-CRC samples. The expression of CD3, CD8, programmed death-1, and programmed death ligand-1 protein was evaluated on a subset of samples by immunohistochemistry, and lymphocyte density was calculated. A subset of deregulated genes was identified. Functional clustering analysis performed on these genes generated four main factors: antigen processing and presentation, with its major histocompatibility complex-II-related genes; genes correlated with the cytotoxic activity of immune system; ...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
To understand the immune landscape of deficient mismatch repair colorectal cancer (dMMR CRC) tumor m...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
Abstract Background Currently, mismatch repair-deficient (dMMR) status is a promising candidate for ...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
To understand the immune landscape of deficient mismatch repair colorectal cancer (dMMR CRC) tumor m...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
Abstract Background Currently, mismatch repair-deficient (dMMR) status is a promising candidate for ...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...
International audienceIn the era of immune checkpoint inhibitors, understanding the metastatic micro...